enGene (ENGN)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from ENGN's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Results from SEC filings
Fiscal years, from enGene's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Net income | -$24M | -$100M | -$55M | -$117M |
| Free cash flow | -$18M | -$25M | -$49M | -$101M |
| EPS (diluted) | $44.30 | $151.22 | $1.46 | $2.29 |
| Operating margin | — | — | — | — |
Superinvestors who own ENGN
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by enGene's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Sep 22, 2026 | William Grossman Interim Chief Medical Officer |
5,102 | $1.97 | $10,051 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when ENGN trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are enGene insiders buying the stock?
1 open-market insider purchase of ENGN in the last 12 months, from SEC Form 4 filings.
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.